Resum6
Les hypolipidemiants, particulierement les inhibiteurs de I'hydroxy-methylglutaryl coenzyme A r6ductase, ont prouve leur efficacit6 en reduisant la mortalite et la morbidite cardiovasculaires chez les patients non ur6miques. La dyslipid6mie est frequente et elle est associ6e aux maladies cardiovasculaires souvent observ6es chez les patients uremiques chroniques. L'efficacite des strat6gies corrigeant la dyslipid6mie reste & d6terminer chez ces patients. © 1999 Elsevier, Paris accidents cardiovasculaires / atherome / HMGCoA r6ductase / hyperlipidemie / ur6mie Summary -Lipids and cardiovascular diseases in chronic renal failure.
Lipid lowering therapies, particularly the inhibitors of hydroxy-methylglutaryl coenzyme A reductase, have been clearly shown to reduce cardiovascular morbidity and mortafity in non-uremic patients.
Dyslipidemia is a common feature in uremic patients, and is well correlated with the high incidence of cardiovascular morbidity and mortafity in these patients. The efficacy of hypolipidemic strategies in reducing cardiovascular events remains to be determined in these patients. © 1999 Elsevier, Paris cardiovascular events / atherosclerosis / HMGCoA reductase / hyperlipidemia / chronic renal failure * Correspondance et tir6s ~t part.